Cat. No.: DAB-0012244
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB, IP, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly449 of human LSR protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | LSR |
| UniProt No. | Q86X29 |
| Gene ID | 51599 |
| Gene Description | The lipolysis-stimulated lipoprotein receptor is an immunoglobulin superfamily member and single pass transmembrane protein that binds the apolipoprotein B and apolipoprotein E lipoproteins. LSR is responsible for the cellular uptake of triacylglyceride-rich lipoproteins and supports lipid distribution between the liver and peripheral tissues. The LSR protein is expressed at the cell membrane as a heterodimer consisting of α and β subunits, which are produced as alternative splice variants from a single gene. Research studies suggest that LSR acts as the host cell surface receptor for multiple Clostridium toxins and participates in the formation of tricellular tight junctions in epithelial cells. Additional studies demonstrate that LSR expression is up-regulated in several cancer types, including breast, bladder, and colorectal cancer, which could lead to pro-tumorigenic changes in metabolism. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
